Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the most intriguing developments in regenerative medicine: epigenetic ...

Adani Mundra Airport has commenced scheduled commercial flight operations with Star Air's inaugural service from Goa. The ...

Scientists have taken a small but significant step toward testing the idea of reverse aging in humans. Researchers have ...

Pleased to announce the first patient has been dosed in our Phase 1 clinical trial, evaluating our lead candidate for optic ...

A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

The first participant has been treated in a landmark clinical trial of cellular reprogramming, which aims to rejuvenate aging ...

World’s first anti-ageing gene therapy trial begins as ER-100 is injected into a human eye, testing partial cellular reprogramming to restore vision and fight ageing ...

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis HTX-001 is a first-in-class ...

I’ve covered the ageing field for many years and seen a lot of promising rejuvenation therapies get hyped up then fall flat on their faces. Ground zero for this repeated cycle was resveratrol, a ...